Kymera Therapeutics Inc (KYMR)

07:16 AM

Kymera Therapeutics to Participate in Upcoming May Investor Conferences - The Manila Times

07:16 AM

07:06 AM

Kymera lines up two May investor webcasts from Las Vegas and New York - Stock Titan

07:06 AM

07:00 AM

Kymera Therapeutics to Participate in Upcoming May Investor Conferences - GlobeNewswire Inc.

07:00 AM

May 05, 2026

Kymera presents preclinical data for IBD drug candidate KT-579 - Investing.com UK

May 05, 2026

May 05, 2026

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week - Investing News Network

May 05, 2026

May 05, 2026

Kymera presents preclinical data for IBD drug candidate KT-579 By Investing.com - Investing.com Australia

May 05, 2026

May 05, 2026

Equities Analysts Issue Forecasts for KYMR Q2 Earnings - MarketBeat

May 05, 2026

May 05, 2026

Oral bowel disease drug matched approved therapies in preclinical tests - Stock Titan

May 05, 2026

May 04, 2026

Kymera Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-05-04 - Seeking Alpha

May 04, 2026

May 04, 2026

Kymera Therapeutics Q1 2026 earnings preview - MSN

May 04, 2026

May 04, 2026

Kymera Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq

May 04, 2026

May 04, 2026

Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq

May 04, 2026

May 04, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance

May 04, 2026

May 03, 2026

Understanding Momentum Shifts in (KYMR) - Stock Traders Daily

May 03, 2026

May 02, 2026

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Kymera Therapeutics (KYMR) and Teleflex (TFX) - The Globe and Mail

May 02, 2026

May 02, 2026

Kymera expects KT-579 phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end - MSN

May 02, 2026

May 02, 2026

Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Axsome Therapeutics (AXSM) and Kymera Therapeutics (KYMR) - The Globe and Mail

May 02, 2026

May 02, 2026

Jennison Associates LLC Decreases Stock Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

May 02, 2026

May 02, 2026

Kymera Therapeutics (NASDAQ:KYMR) Upgraded to Hold at Wall Street Zen - MarketBeat

May 02, 2026

May 01, 2026

Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $119 - Moomoo

May 01, 2026

May 01, 2026

KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration - Yahoo Finance

May 01, 2026

May 01, 2026

HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN

May 01, 2026

May 01, 2026

Kymera Therapeutics, Inc. (KYMR) reports Q1 loss, tops revenue estimates - MSN

May 01, 2026

May 01, 2026

Kymera Q1 2026 slides: immunology pipeline advances, revenue surges By Investing.com - Investing.com Australia

May 01, 2026

May 01, 2026

Kymera Therapeutics Inc (KYMR) Q1 2026 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - GuruFocus

May 01, 2026

May 01, 2026

KYMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

May 01, 2026

Apr 30, 2026

Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results, Beats Expectations By $0.18 EPS - MarketBeat

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat

Apr 30, 2026

Apr 30, 2026

Key Risks and Forward-Looking Statements in Kymera Therapeutics, Inc. Q1 2026 10-Q Report - Minichart

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics Q1 Earnings Call Highlights - MarketBeat

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics Reports Q1 2026 Financial Results, Highlights Pipeline Progress and $1.55B Cash Runway into 2029 - Minichart

Apr 30, 2026

Apr 30, 2026

Kymera shifts KT-579 data to 2H 2026, keeps KT-621 on track - MSN

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

Apr 30, 2026

Apr 30, 2026

Earnings call transcript: Kymera Therapeutics beats Q1 2026 earnings forecasts By Investing.com - Investing.com Australia

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics (KYMR) Achieves Strong Q1 Revenue Performanc - GuruFocus

Apr 30, 2026

Apr 30, 2026

Earnings call transcript: Kymera Therapeutics beats Q1 2026 earnings forecasts - Investing.com

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics Shares Fall After Q1 Loss Narrows, Collaboration Revenue Rises - Moomoo

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update - Investing News Network

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

Apr 30, 2026

Apr 30, 2026

Is Kymera Therapeutics (KYMR) 418.1% Overvalued After Q1 2026 Be - GuruFocus

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics (NASDAQ:KYMR) Soars on Q1 2026 Revenue and EPS Beat - ChartMill

Apr 30, 2026

Apr 30, 2026

Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.88 Loss - marketscreener.com

Apr 30, 2026

Apr 30, 2026

Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q1 Revenue $34.4M, vs. FactSet Est of $8.3M - marketscreener.com

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics (NASDAQ: KYMR) grows collaboration revenue but stays in loss - Stock Titan

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics (NASDAQ: KYMR) Q1 2026 results and $45M Gilead milestone - Stock Titan

Apr 30, 2026

Apr 30, 2026

Press Release: Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update - Moomoo

Apr 30, 2026

Apr 30, 2026

Pictet Asset Management Holding SA Has $37.79 Million Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Apr 30, 2026

Apr 30, 2026

Kymera Therapeutics (KYMR) Q1 2026 Deepening Losses Test Bullish Revenue Growth Narrative - Sahm

Apr 30, 2026

Apr 29, 2026

Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Stock - MarketBeat

Apr 29, 2026

Apr 29, 2026

Kymera Therapeutics CEO Nello Mainolfi sells $2.4m in stock By Investing.com - Investing.com Nigeria

Apr 29, 2026

Apr 29, 2026

Kymera Therapeutics CEO Nello Mainolfi sells $2.4m in stock - Investing.com

Apr 29, 2026